
    
      Current practice guidelines recommend only sorafenib for patients with hepatocellular
      carcinoma invading major intrahepatic vessels. However, recent data from observational
      studies suggest that the combination of transarterial chemoembolization and external beam
      radiotherapy would be as effective as sorafenib.
    
  